Back to Stocks

MASI

MASIMO CORP
7 filings tracked
healthcaremedical devicesMID ($2B-10B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Masimo is successfully transitioning into a pure-play healthcare technology leader, demonstrating resilient growth and operational discipline.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optimistic headline growth, Masimo's financial health shows signs of underlying stress.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every MASI filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The latest filing presents a company at a critical crossroads, balancing strong product demand against significant corporate turbulence. On one hand, the core healthcare business is thriving, with revenue growth and a successful pivot away from consumer electronics. On the other hand, the balance sheet is under pressure from rising debt and a cascade of legal challenges that threaten to erode the gains made by the operational turnaround. The overarching narrative for investors is now dominated by the Danaher merger. While the $180-per-share price tag provides a clear valuation target, the path to closing involves navigating a complex landscape of litigation and integration risks. The ability of the company to maintain its healthcare momentum while resolving its legacy legal disputes will determine whether the merger is a seamless transition or a fraught acquisition of a distressed asset.

Selected Quarter

Core Takeaway

Masimo is successfully scaling its core healthcare platform, but corporate legal battles and margin pressure are creating significant volatility ahead of the Danaher merger.

Investor Lens

Investors must weigh the certainty of the Danaher merger price against the risk of escalating legal settlements and liquidity drains.

Watch Next

The final closing of the Danaher merger and the outcome of the Apple pulse oximeter appeals.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.45Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 5

Revenue grew 8.5% to $403.6 million, driven by core healthcare demand.

earnings beat
70%
bearishMay 5

Gross margin slipped to 62.1% due to tariffs and input cost inflation.

margin compression
40%
bullishMay 5

Definitive merger agreement with Danaher at $180 per share.

acquisition
90%
bullishMay 5

Completed sale of non-healthcare consumer business to Samsung/Harman.

divestiture
60%
bullishMay 5

Revenue grew 8.5% to $403.6 million, driven by core healthcare demand.

earnings beat
70%
bearishMay 5

Gross margin slipped to 62.1% due to tariffs and input cost inflation.

margin compression
40%
bullishMay 5

Definitive merger agreement with Danaher at $180 per share.

acquisition
90%
bullishMay 5

Completed sale of non-healthcare consumer business to Samsung/Harman.

divestiture
60%
bullishMay 5

Revenue grew 8.5% to $403.6 million, driven by core healthcare demand.

earnings beat
70%
bearishMay 5

Gross margin slipped to 62.1% due to tariffs and input cost inflation.

margin compression
40%
bullishMay 5

Definitive merger agreement with Danaher at $180 per share.

acquisition
90%
bullishMay 5

Completed sale of non-healthcare consumer business to Samsung/Harman.

divestiture
60%
bullishMay 5

Revenue grew 8.5% to $403.6 million, driven by core healthcare demand.

earnings beat
70%
bearishMay 5

Gross margin slipped to 62.1% due to tariffs and input cost inflation.

margin compression
40%
bullishMay 5

Definitive merger agreement with Danaher at $180 per share.

acquisition
90%
bullishMay 5

Completed sale of non-healthcare consumer business to Samsung/Harman.

divestiture
60%
bullishMay 5

Revenue grew 8.5% to $403.6 million, driven by core healthcare demand.

earnings beat
70%
bearishMay 5

Gross margin slipped to 62.1% due to tariffs and input cost inflation.

margin compression
40%
bullishMay 5

Definitive merger agreement with Danaher at $180 per share.

acquisition
90%
bullishMay 5

Completed sale of non-healthcare consumer business to Samsung/Harman.

divestiture
60%
bullishMay 5

Revenue grew 8.5% to $403.6 million, driven by core healthcare demand.

earnings beat
70%
bearishMay 5

Gross margin slipped to 62.1% due to tariffs and input cost inflation.

margin compression
40%
bullishMay 5

Definitive merger agreement with Danaher at $180 per share.

acquisition
90%
bullishMay 5

Completed sale of non-healthcare consumer business to Samsung/Harman.

divestiture
60%
bullishMay 5

Revenue grew 8.5% to $403.6 million, driven by core healthcare demand.

earnings beat
70%
bearishMay 5

Gross margin slipped to 62.1% due to tariffs and input cost inflation.

margin compression
40%
bullishMay 5

Definitive merger agreement with Danaher at $180 per share.

acquisition
90%
bullishMay 5

Completed sale of non-healthcare consumer business to Samsung/Harman.

divestiture
60%

Filing History

10-QMay 5, 2026
Expand Sequence

The latest filing presents a company at a critical crossroads, balancing strong product demand against significant corporate turbulence. On one hand, the core healthcare business is thriving, with revenue growth and a successful pivot away from consumer electronics. On the other hand, the balance sheet is under pressure from rising debt and a cascade of legal challenges that threaten to erode the gains made by the operational turnaround. The overarching narrative for investors is now dominated by the Danaher merger. While the $180-per-share price tag provides a clear valuation target, the path to closing involves navigating a complex landscape of litigation and integration risks. The ability of the company to maintain its healthcare momentum while resolving its legacy legal disputes will determine whether the merger is a seamless transition or a fraught acquisition of a distressed asset.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.